Pharmaceutical

IBI-322 by Innovent Biologics for Lymphoma: Likelihood of Approval

IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma.

Dec 22, 2023 - 18:00
IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma.
Read the original article

Tags:

Previous Article

Opinion: The U.S. must raise federal alcohol taxes to address the alarming rise ...

Next Article

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Trailing other sickle cell drug makers, Editas still sees opportunity for its CRISPR therapy

STAT+: Trailing other sickle cell drug makers, Editas s...

Jun 10, 2023

More colonoscopy news and research

More colonoscopy news and research

Nov 29, 2023

STAT+: Key Senate panel to consider PBM, drug pricing reform package

STAT+: Key Senate panel to consider PBM, drug pricing r...

Nov 3, 2023